黛安神加匹维溴胺与单剂匹维溴胺治疗肠易激综合征的疗效比较

目的比较黛安神联合匹维溴胺与单剂匹维溴胺治疗肠易激综合症的疗效.方法将108例肠易激综合征病人随机分为2组,治疗组56例(男23例,女33例,年龄41a+10d)应用黛安神(Deanxit)1片PO.Bid加匹维溴胺(Pinaveriumbromide)50毫克PO.Tid简称D-P组,对照组52例(男20例,女32例,年龄44a±11a),应用单剂匹维溴胺50毫克PO.Tid简称P组.疗程均为4周.结果治疗组总有效率为100%.对照组为81%(χ2P＜0.01).治疗组对缓解腹痛、腹胀、腹泻、便秘、粘液便优于对照组,特别对腹痛、腹胀疗效更为明显.结论黛安神联合匹维溴胺是治疗肠易激综合征更有效的药物治疗方法.     

匹维溴铵单用及联用黛力新治疗肠易激综合征的疗效观察

目的:观察匹维溴铵及匹维溴铵联用黛力新对肠易激综合征(IBS)患者治疗的效果。方法:按罗马Ⅱ标准选择126例IBS患者随机分为两组,每组63例。仅予匹维溴铵治疗者     

黛力新联合匹维溴胺治疗肠易激综合征疗效观察

目的观察及评价黛力新联合匹维溴胺治疗肠易激综合征(IBS)的疗效。方法对78例IBS患者随机分成治疗组42例和对照组36例,治疗组给予黛立新片2片/d,早晨和中午各1片口服,匹维溴胺片50mg,3次/d;对照组单用匹维溴胺片50mg,3次/d。两组疗程均为8周。治疗期间均停用其他药物。观察比较两组疗效。结果治疗组治疗8周的总有效率为83.3%,疗效明显高于对照组的44.4%,差异有统计学意义(P0.01)。结论黛力新联合匹维溴胺治疗IBS疗效较好,值得临床推广使用。     

匹维溴铵治疗肠易激综合征的临床疗效及改变肛门直肠动力和内脏敏感性研究

目的　探讨匹维溴铵对肠易激综合征 (IBS)患者的疗效 ,及对腹泻型和便秘型IBS肛门直肠压力和内脏敏感性的影响。方法　按罗马Ⅱ标准选择 84例IBS患者 ,均予匹维溴铵 5 0mg口服 ,每日 3次。分别于服药前、服药 1周和 2周后对各种症状的改善情况进行评估。对 14例腹泻型IBS及 10例便秘型IBS患者分别于服药前和服药 2周后进行肛门直肠压力及直肠敏感性测定。结果　服用匹维溴铵 1周后 ,腹痛、腹胀和黏液便症状评分改善 ,差异有非常显著性 (各为 2 .13± 0 .36比 1.2 8± 0 .35 ,2 .4 9± 0 .73比 1.35± 0 .17,1.0 3± 0 .2 7比 0 .4 3± 0 .12 ,P <0 .0 1) ,腹泻、便秘及里急后重症状评分显著改善 (2 .4 2± 0 .33比 2 .10± 0 .2 7,2 .0 7± 0 .4 5比 1.6 7± 0 .36 ,1.98± 0 .2 9比 1.6 8± 0 .2 7,P <0 .0 5 )。服用2周后 ,除排便困难外 ,IBS各症状评分均改善 ,差异有非常显著性 (P <0 .0 1)。腹泻型IBS内脏感觉阈值、排便阈值及疼痛阈值均有非常显著提高 (2 4 .39± 12 .0 7比 4 9.88± 7.14 ,34.2 5± 14 .77比 6 8.93±2 1.82 ,70 .2 1± 18.17比 10 4 .6 9± 4 3.2 3,P <0 .0 1)。便秘型IBS肛管括约肌静息压减低 ,差异有非常显著性 (84 .37± 4 3.76比 71.4 7± 2 9.88,P <0 .0 1) ,收缩压和舒张     

匹维溴胺联合谷维素治疗肠易激综合征疗效评议

目的探讨匹维溴胺联合谷维素治疗肠易激综合征（IBS）的临床疗效。方法选择36例IBS患者，随机分为对照组及治疗组各18例。对照组采用匹维溴胺治疗，50mg／次，3次／d；治疗组在此基础上服用谷维素，30mg／次，3次／d，疗程均为1个月。观察两组治疗前后的临床疗效、症状、体征。结果治疗组总有效率为94．44％，对照组总有效率为83．33％，治疗组与对照组比较，差异有显著性（P〈0．05）。治疗组对缓解腹痛、腹泻、便秘等症状优于对照组。结论匹维溴胺联合谷维素组可有效改善IBS患者的临床症状，提高疗效。     

中西医结合治疗腹泻型肠易激综合征60例

[目的]观察中医药联合匹维溴胺(商品名:得舒特)治疗腹泻型肠易激综合征(IBS)的疗效.[方法]将118例腹泻型IBS患者随机分为2组,治疗组60例,给予中药疏肝健脾剂配合匹维溴胺50 mg口服,每日3次;对照组58例,给予口服匹维溴胺50 mg,每日3次.[结果]治疗4周后,治疗组总有效率96.8%,对组照80.2%,2组比较差异有统计学意义(P＜0.05).[结论]中医药联合匹维溴胺治疗腹泻型IBS有较好的疗效.     

匹维溴铵对肠易激综合征患者回盲部肥大细胞脱粒的影响

目的评价匹维溴胺对腹泻型肠易激综合征(ir-ritable bowel syndrome,IBS)的临床疗效以及对回盲部肥大细胞脱粒的影响,探讨其治疗腹泻型IBS的可能机制。方法应用匹维溴胺治疗符合入选标准的IBS患者48例,观察其对腹泻型患者的疗效,并以便秘型患者作对照,同时检测治疗前后IBS患者回盲部脱颗粒肥大细胞的数目变化。结果匹维溴胺治疗腹泻型IBS疗效明显,治疗前后腹泻型IBS患者脱颗粒肥大细胞数目有显著变化。结论匹维溴胺治疗腹泻型IBS有效,可能与抑制了肥大细胞的脱粒有关。     

痛泻要方加味联合黛力新治疗肠易激综合征60例

目的:观察中药痛泻要方加味联合黛力新治疗肠易激综合征(IBS)的临床疗效.方法:将110例IBS患者随机分为观察组(n=60)和对照组(n=50),分别采用中药痛泻要方加味联合黛力新及单用中药痛泻要方加味治疗1 mo.观察两组有效率、不良反应.结果:观察组和对照组总有效率分别为100%,84%(P＜0.05).腹痛、腹胀、腹泻单项症状总有效率观察组分别为100%,96%,93%,而对照组分别为88%,81%,81%(P均＜0.05);便秘、黏液便总有效率观察组与对照组无显著差异60＞0,05).观察组治疗期间未发现明显不良反应.结论:中药痛泻要方加味联合黛力新能快速消除和改善患者腹痛、腹胀、腹泻等症状,显著提高临床治疗效果,无明显不良反应.     

浙江省IBS就诊人群临床分型特点的研究

目的总结浙江省IBS人群不同亚型的发病特点.探讨符合我国IBS人群的临床分型标准.方法通过浙江省消化中心全省网络,从2001年1月至2002年1月,收集各医院消化科门诊就诊的符合罗马Ⅱ诊断标准的IBS患者540例,并按患者的排便习惯分为三型即腹泻为主型(IBS-D),便秘为主型(IBS-C)和腹泻便秘交替型(IBS-A).其中126例接受匹维溴胺100 mgt.i.d 8周治疗,观察匹维溴胺对不同亚型IBS的疗效差异.本研究采用问卷调查方式,问卷内容包括一般资料、症状问卷量表和生活质量量表(SF-36).结果①在IBS-C和IBS-A患者中,女性明显高于男性,而IBS-D患者中,男性更为多见(P＜0.05).IBS-D的患者饮酒的比例明显高于IBS-C的患者(P＜0.05).IBS-D吸烟的比例明显高于IBS-A的患者(P＜0.05).年龄分布在不同亚型患者无显著差异;②不同亚型的IBS中IBS-D占47.8%,IBS-A为32.2%,IBS-C为20.0%.不同亚型IBS患者的结肠症状和结肠外症状分布有所不同.腹痛≥1 h/d和腹痛频率≥2d/周在IBS-A最多见,而IBS-D患者较多出现黏液便、焦虑和消化不良(P＜0.05);③SF-36生活质量显示三个亚型IBS患者均在活力、总体健康和精神健康维度的生活质量下降尤为明显.IBS-C患者的生活质量普遍低于另外两型.IBS-C患者的生理功能、情感职能、总体健康和精神健康维度的生活质量显著低于IBS-D患者(P＜0.05);④匹维溴胺对IBS-C的总有效率和显效率分别60.8%和30.4%,IBS-D分别为94.9%和57.6%,IBS-A分别为77.3%和59.1%.匹维溴胺治疗不同亚型的IBS患者总有效率和显效率比较均有显著差异(P＜0.05).匹维溴胺对IBS-C患者的显效率显著低于另外两型(P＜0.05).结论按排便习惯分型的IBS患者在流行病学、临床表现、生活质量及对治疗反应等方面均有一定的差异,这一分型对临床有一定的指导意义.     

匹维溴铵治疗腹泻型肠易激综合征的临床观察

目的 观察匹维溴铵对腹泻型肠易综合征(IBS)的治疗效果.方法 95例腹泻型肠易激综合征患者接受匹维溴铵治疗2周,观察患者治疗前后腹痛、腹胀、腹泻、大便形态、生活质量改善以及药物副反应.结果 接受匹维溴铵治疗2周后,腹泻型lBS患者腹痛、腹胀和腹泻症状评分均较治疗前显著降低(P＜0.05),大便性状评分较治疗前下降(P＜0.05),生活质量评分较治疗前提高(P＜0.05).但在停药结束后4周上述指标评分较治疗前无明显差异(P＞0.05).结论 匹维溴铵可有效缓解腹泻型lBS患者的临床症状,但治疗疗程值得进一步研究.     

马来酸曲美布丁联合匹维溴胺治疗肠易激综合征的疗效观察

目的观察马来酸曲美布丁联合匹维溴胺治疗肠易激综合征的疗效。方法将100例肠易激综合征患者随机分为2组：实验组（57例）应用马来酸曲美布丁0.1g tid、匹维溴胺50 mg tid治疗;对照组（43例）应用匹维溴胺50 mg tid治疗,疗程均为4周。结果实验组总有效率88%,对照组总有效率74%,存在显著性差异。结论马来酸曲美布丁联合匹维溴胺治疗肠易激综合征的疗效更好。     

认知治疗联合匹维溴胺、益生菌治疗腹泻型肠易激综合征

目的探讨认知治疗结合匹维溴铵、益生菌治疗腹泻型肠易激综合征（D-IBS）的可行性。方法符合罗马Ⅲ标准的62例D-IBS患者随机分为2组,A组：匹维溴胺（50 mg/次,3次/d）＋双歧三联活菌制剂（粪链球菌、嗜酸乳杆菌、双歧杆菌3种肠道固有菌的活菌制剂）（420 mg/次,3次/d）;B组：认知治疗＋匹维溴胺（50 mg/次,3次/d）＋双歧三联活菌制剂（420 mg/次,3次/d）,疗程为8周。分别记录治疗前后患者SF-36生活质量评分和症状积分。结果 A组症状显效率和总有效率分别为35.5%和77.4%;B组分别为54.8%和90.3%;B组治疗后,患者生活质量明显改善,躯体疼痛（BP）、总体健康（GH）、活力（VT）、社会功能（SF）、情感职能（RE）和精神健康（MH）维度的积分有显著提高（P〈0.05）,优于A组。结论认知治疗联合匹维溴胺和益生菌对改善患者的生活质量和IBS症状疗效优越。     

认知治疗联合益生菌、匹维溴胺治疗腹泻型肠易激综合征的临床研究

目的本研究试图评价应用认知治疗联合益生菌、匹维溴胺治疗腹泻型肠易激综合征(diarrhea-preclomnant irritable bowelsyndrons,D-IBS)的有效性和安全性。方法符合罗马Ⅲ标准的90例D-IBS患者接受认知治疗、匹维溴胺(50 mg/次,3次/d)、双岐三联活菌制剂(粪链球菌、嗜酸乳杆菌、双歧杆菌3种肠道固有菌的活菌制剂)(420 mg/次,3次/d)共8周,分别记录治疗前后患者SF-36生活质量评分和症状积分以评价疗效;治疗前后对粪便菌丛进行记数,对粪便中5种细菌进行培养并对集落形成单位进行记数;治疗前后用不透X线标志物测定全结肠通过时间来评价结肠运输时间的变化;应用SPSS软件对试验数据进行统计学分析。结果有81例患者完成了本研究;试验过程中未发现不良反应;对于D-IBS患者的治疗,认知治疗联合匹维溴胺、益生菌的总有效率达88.9%,症状改善明显尤其是对于腹痛、大便性状的改善;患者生活质量明显改善,躯体疼痛(BP)、总体健康(GH)、活力(VT)、社会功能(SF)、情感职能(RE)和精神健康(MH)维度的积分有显著提高(P<0.05);益生菌能够明显增加肠道双歧杆菌(P<0.01)和乳酸杆菌(P<0.05),明显减少肠球菌(P<0.01)和类杆菌(P<0.05),而肠杆菌无显著变化(P>0.05);结肠运输时间延迟显著(P<0.05)。结论认知治疗联合匹维溴胺和益生菌治疗D-IBS是安全、有效的。     

文拉法辛缓释片与匹维溴铵治疗无明显情绪障碍腹泻型肠易激综合征的初步研究

背景：目前对选择性5-羟色胺再摄取抑制剂（SSRIs）可用于治疗伴抑郁或焦虑状态的肠易激综合征（IBS）已基本达成共识,但关于SSRIs治疗无明显情绪障碍IBS的研究相对较少。目的：评价5-羟色胺去甲肾上腺素再摄取抑制剂文拉法辛缓释片与匹维溴铵对无明显情绪障碍、长期反复发作腹泻型IBS（IBS—D）的治疗作用。方法：本临床研究协作组前期关于文拉法辛缓释片与匹维溴铵治疗IBS．D的随机对照多中心研究中,376例患者完成观察。23例经汉密尔顿抑郁量表（HAMD）和汉密尔顿焦虑量表（HAMA）评价为无明显抑郁、焦虑状态者中,对照组7例（口服匹维溴铵8周）,试验组16例（口服文拉法辛缓释片与匹维溴铵8周）。比较两组患者的症状评分和HAMD、HAMA评分以及总有效率。结果：服药1周后起,试验组腹痛、腹泻评分和症状总评分均显著低于对照组（P〈0．05）;服药4周后起,试验组HAMD、HAMA评分亦显著低于对照组（P〈0．05）。试验组总体症状改善的总有效率显著高于对照组（87．5％对28．6％,P〈0．05）。结论：文拉法辛缓释片与匹维溴铵可改善无明显情绪障碍IBS-D患者的核心症状和不良情绪因子,疗效明显优于单用匹维溴铵。     

赛乐特联合匹维溴铵治疗肠易激综合征

目的 观察匹维溴铵、赛乐特对肠易激综合征的疗效。方法 98例随机分为两组,实验组(S组)58例,赛乐特20mg,1次/日,匹维溴铵薄膜包衣片50mg,每天3次;对照组(P组)40例;单用匹维溴铵50mg,每天3次,两组均每3天进行心理疏导1次,4周为1个疗程。结果 S组显效率58.62％,有效率37.93％,总有效率96.55％;P组显效率47.50％,有效率32.50％,总有效率80％(P<0.05)。结论 赛乐特,匹维溴铵联合治疗肠易激综合征较单用匹维溴铵疗效好。     

Comparison of acupuncture and pinaverium bromide in the treatment of irritable bowel syndrome: A protocol for systematic review and meta-analysis

Background:Irritable bowel syndrome (IBS) is one of the most common chronic gastrointestinal diseases, and the current diagnosis of IBS is still based on symptoms and examination. Pinaverium bromide is commonly used as an antispasmodic in the treatment of IBS. But adverse effects of pinaverium bromide are common. Meta-analyses show that acupuncture has a positive therapeutic effect on IBS.Methods:Randomized controlled trials of comparing the efficacy of acupuncture and pinaverium bromide in the treatment of IBS will be searched in the relevant database: PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Database, Chinese Biomedical Literature Database (CBM), and Chinese Scientific Journal Database (VIP database). The studies selected will be exported to EndNote V.9.1 software. Data will be carried out independently from the selected articles by 2 reviewers. Any disagreement will be solved in consultation with a third reviewer.Results:Our study aims to compare the efficacy of acupuncture and pinaverium bromide in the treatment of IBS and to fill the lack of relevant evidence.Conclusion:Through the inclusion of relevant literature, the overall efficacy of acupuncture and pinaverium bromide in the treatment of IBS will be evaluated, and the gap between various acupuncture treatment measures will be further analyzed.INPLASY registration number:INPLASY 202130068.     

Octylonium bromide in the treatment of the irritable bowel syndrome: a clinical-functional study.

We investigated the effect of octylonium bromide on a number of symptoms and functional aspects of the irritable bowel syndrome. Seventy-two patients complaining mainly of abdominal pain were studied in a double-blind trial (octylonium bromide 40 mg tid for 4 weeks or placebo). Clinical parameters were: abdominal pain, bloating and bowel frequency. Sigmoid manometry with simultaneous recording of the thresholds for distension and/or pain upon graded inflation of an endoluminal balloon was performed before and at the end of treatment. In contrast to placebo, octylonium bromide significantly reduced pain and bloating, and significantly increased (p < 0.02) the pain threshold throughout the treatment period. However, comparison with the placebo group failed to show any relevant differences. Neither treatment influenced the frequency of bowel movement. Sigmoid motility during distension was significantly reduced after octylonium bromide (p < 0.05), but it did not change after placebo. In conclusion, octylonium bromide is capable of reducing symptoms and motor reactivity of the sigmoid in patients with irritable bowel syndrome.     

Extended analysis of a double-blind,placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome

BACKGROUND/OBJECTIVE: In order to follow the most recent developments and recommendations in trial methodology for drug evaluation in patients with irritable bowel syndrome, we performed an extended analysis of a large clinical trial from a previously published study of otilonium bromide, using an assessment that integrates the key symptoms of irritable bowel syndrome. MATERIALS AND METHODS: A large-scale clinical trial with a double-blind, placebo-controlled, parallel-group study design was conducted in 378 patients, treated for 15 weeks with the recommended standard dose of 40 mg otilonium bromide or placebo three times daily. The study was based on the collection of 12 single efficacy endpoints. The new efficacy assessment was based on the data reported by the patients. Rather than demonstrating score differences between the treatment groups of the study, we carried out an assessment that integrates the most frequent symptoms reported (pain frequency and intensity, presence of meteorism and distension) by the patient. RESULTS: The rate of response to treatment within 2-4 months (the primary efficacy outcome measure) was significantly higher in the otilonium bromide group (36.9%) than in the placebo group (22.5%; P = 0.007). In each month of treatment, the rate of monthly response was higher in the otilonium bromide group as compared to the placebo group (P < 0.05). The total monthly and weekly responses to the single endpoints (intensity and frequency of pain and discomfort, meteorism/abdominal distension, severity of diarrhoea or constipation and mucus in the stool) were significantly more frequent in the group treated with otilonium bromide than in the placebo-treated group, with differences ranging from 10% to 20%. The subgroup analysis of the intestinal habits endpoint indicates that patients with diarrhoea have an additional benefit. CONCLUSION: The present re-evaluation of a previously published study confirms that otilonium bromide is more effective than placebo for the treatment of irritable bowel syndrome, being very efficient in relieving pain and discomfort.